

The Opioid Epidemic – What the Oral and Maxillofacial Surgeon Needs to Know

Matthew Hamedani

Oral and Maxillofacial Surgery Resident

Jackson Memorial Hospital – University of Miami

Jackson
MEMORIAL HOSPITAL




UHealth
UNIVERSITY OF MIAMI HEALTH SYSTEM

UNIVERSITY OF MIAMI
MILLER SCHOOL
of **MEDICINE**

Disclosure

- I have no actual or potential conflict of interest in relation to this program/presentation.
- I disclose that I have no relevant financial relationships with commercial interests



Prescription Opioid Abuse Is a Critical Public Health Issue



THE OPIOID EPIDEMIC BY THE NUMBERS

IN 2016...



116
People died every day
from opioid-related
drug overdoses



11.5 m
People misused
prescription opioids¹



42,249
People died from
overdosing on opioids²



2.1 million
People misused prescription
opioids for the first time¹



2.1 million
People had an opioid use
disorder¹



17,087
Deaths attributed to
overdosing on commonly
prescribed opioids²



948,000
People used heroin¹



19,413
Deaths attributed to overdosing
on synthetic opioids other than
methadone²



170,000
People used heroin for
the first time¹




15,469
Deaths attributed to
overdosing on heroin²




504 billion
In economic costs³

Sources: ¹ 2016 National Survey on Drug Use and Health, ² Mortality in the United States, 2016 NCHS Data Brief No. 293, December 2017, ³ CEA Report: The underestimated cost of the opioid crisis, 2017

Prescription Drug Abuse – How did this start?





The Opioid Epidemic – What is our role?

- In 1998, Dentists were the top specialty of prescribers of immediate-release opioids, accounting for 15.5% of all opioid prescriptions in the U.S.
- By 2012 this number had fallen to 6.4%
- Oral and Maxillofacial Surgeons primarily manage acute pain and pain medication prescribed following surgery may frequently be the first exposure many American adolescents have to opioid prescriptions.
- Opioid prescribing rates have increased between 2010-2015, with the largest increase being among 11-18 year-olds.





COCAINE TOOTHACHE DROPS

Instantaneous Cure!

PRICE 15 CENTS.

Prepared by the

LLOYD MANUFACTURING CO.

219 HUDSON AVE., ALBANY, N. Y.

For sale by all Druggists.

(Registered March 1885.)

See other side. 19

House Bill 21 - Control Substances Act

- Signed by the Governor on March 19, 2018 with an effective date of **July 1, 2018**.
- The law addresses opioid abuse by establishing prescribing limits, requiring continuing education on controlled substance prescribing, expanding required use of Florida's Prescription Drug Monitoring Program (EFORCSE) and more.

Required Course

- Each prescribing practitioner who is registered with the United States Drug Enforcement Agency, is required to take a Board-approved continuing education course.
- Florida Board of Dentistry
- Contains information on:
 - Current standards
 - Nonpharmacological therapy
 - Emergency opioid antagonists
 - Risk of opioid addiction following all stages of the treatment of acute pain
- The course must be completed by **January 31, 2019**, and at each subsequent licensure renewal.

Standards of Practice for Treatment of Acute Pain

Acute Pain

- Defined as “the normal, predicted, physiological, and time-limited response to an adverse chemical, thermal, or mechanical stimulus associated with surgery, trauma, or acute illness.”
 - Legislature exempted from this definition pain related to:
 - Cancer
 - Terminal illness
 - Provision of relief for symptoms related an incurable, progressive illness or injury (chronic nonmalignant pain)
 - Palliative care
 - Serious traumatic injuries

Prescribing Limitations Schedule II Opioids

Treatment of **Acute Pain**:

- May not exceed 3-day supply
- 7-day supply may be prescribed if:
 - The prescriber, in his or her professional judgment, believes that more than a 3-day supply of such an opioid is medically necessary to treat the patient's pain as an acute medical condition
 - The prescriber indicates "ACUTE PAIN EXCEPTION" on the prescription; AND
 - The prescriber adequately documents in the patients medical records the acute medical condition and lack of alternative treatment options that justify deviation from the 3-day supply limit

Prescribing Limitations Schedule II Opioids

Treatment of **Non-Acute Pain**:

- Prescriber must indicate “NONACUTE PAIN” on a prescription for an opioid drug listed as a Schedule II controlled substance

Prescribing Emergency Opioid Antagonist


- For the treatment of pain related to a traumatic injury with an Injury Severity Score of 9 or greater, a prescriber who prescribes a Schedule II controlled substance listed in s. 893.03 or 21 U.S.C. s. 812 must concurrently prescribe an emergency opioid antagonist, as defined in s. 381.887(1)

| Region | Injury Description | AIS | Square Top Three |
|-------------------------------|--------------------------|-----|------------------|
| Head & Neck | Cerebral Contusion | 3 | 9 |
| Face | No Injury | 0 | |
| Chest | Flail Chest | 4 | 16 |
| Abdomen | Minor Contusion of Liver | 2 | 25 |
| | Complex Rupture Spleen | 5 | |
| Extremity | Fractured femur | 3 | |
| External | No Injury | 0 | |
| Injury Severity Score: | | | 50 |

Opioid Antagonists - Naloxone

IM/SC Auto-Injector (Evzio) – 0.4 mg - 2mg

- Instructions: 0.4-2 mg IM/SC Q 2-3 minutes into anterolateral thigh; not to exceed 10 mg (0.01 mg/kg)
- Onset: 2-5 minutes
- Duration: 30-120 minutes



Intranasal (Narcan) – 4 mg single dose

- Instructions: One spray in alternating nostrils Q 2-3 minutes
- Onset: 8-13 minutes
- Duration: 30-120 minutes



Prescribing Limitations Schedule III Opioids

- For a controlled substance listed in Schedule III, the amount dispensed pursuant to F.S. 465.0276 may not exceed a 14 day supply



Prescription Drug Monitoring Program (PDMP)

- Each prescriber and dispenser or his/her designee must consult the PDMP system each time a controlled substance is prescribed or dispensed to a patient age 16 or older unless a statutory exemption applies.
 - Patient is less than 16 years of age
 - Drug being prescribed is a nonopioid Schedule V
 - System is not operational, as determined by DOH
 - Requestor has technological or electrical failure
 - Under this condition the prescriber must document the reason why the database was not consulted and they cannot give more than a 3 day supply.
- You may register for the PDMP at:
<https://www.floridapmpaware.net>

PDMP Database Access

- You will need to establish an E-FORSCE account to log into the system.
- The following link will take you to the Department of Health's website on accessing the State of Florida PDMP database (E-FORSCE):

<http://www.floridahealth.gov/statistics-and-data/e-forcse/>



PDMP Compliance

- Failure of a prescriber to follow such guidelines constitutes grounds for disciplinary action pursuant to s.456.072(1)(gg), punishable as provided in s. 456.072(2)



He's one of the busiest men in town. While his door may say *Office Hours 2 to 4*, he's actually on call 24 hours a day.

The doctor is a scientist, a diplomat, and a friendly sympathetic human being all in one, no matter how long and hard his schedule.



According to a recent Nationwide survey:

MORE DOCTORS SMOKE CAMELS THAN ANY OTHER CIGARETTE

DOCTORS in every branch of medicine—113,597 in all—were queried in this nationwide study of cigarette preference. Three leading research organizations made the survey. The gist of the query was—What cigarette do you smoke, Doctor?

The brand named most was Camel!

The rich, full flavor and cool mildness of Camel's superb blend of costlier tobaccos seem to have the same appeal to the smoking tastes of doctors as to millions of other smokers. If you are a Camel smoker, this preference among doctors will hardly surprise you. If you're not—well, try Camels now.



Your "T-Zone" Will Tell You...

T for Taste . . .
T for Throat . . .

that's your
proving ground
for any cigarette.
See if Camels
don't suit your
"T-Zone" to a "T."




H. J. Reinhold
Tobacco Company
Washington, D. C.

CAMELS *Costlier Tobaccos*

Things To Take into Consideration

- The choice of analgesic depends on the character, cause and severity of pain
- Start with the lowest effective dose to achieve adequate analgesia
- Prescribe only the number of days that the pain is expected to be severe enough to require opioids.
- Adverse effects should be treated prophylactically where possible
 - Opioid administration should be combined with laxatives to reduce the occurrence of opioid induced constipation
 - Docusate Sodium 50, 100, 240 mg BID
 - Bisacodyl 5, 10 mg QD
- Reassess benefits and risks if considering dose increases

WHO Prescribing Protocol



Used with permission from the World Health Organization.

Multimodal Analgesia

- Combination of APAP and an NSAID effectively lowers pain intensity and decreases the need for supplemental post-operative analgesics better than either drug alone, with minimal adverse effects.
 - Dosing strategies:
 - 800 mg Ibuprofen Q 8 H + 1000 mg APAP Q 6 H
 - 600 mg Ibuprofen Q 6 H + 1000 mg APAP Q 6 H
 - Start medication before anesthesia wears off
- Dose and timing need to be tailored to patient needs and the practitioners expectation of postoperative pain
 - Titrate dose and type of medication to effect
- Need to make sure the maximum dose of either medication is not exceeded

Pre-Emptive Effect of Dexamethasone and Diclofenac Sodium Associated With Codeine on Pain, Swelling, and Trismus After Third Molar Surgery: A Split-Mouth, Randomized, Triple-Blind, Controlled Clinical Trial



Thiago César Lima, DDS, MSc, Elizabete Bagordakis, DDS, MSC, PhD,†
Saulo Gabriel Moreira Falci, DDS, MSC, PhD,‡
Cássio Roberto Rocha dos Santos, DDS, MSC, PhD,§
and Marcos Luciano Pimenta Pinheiro, DDS, MSC, PhD||*

Purpose: We aimed to compare the effect of dexamethasone, 8 mg, and diclofenac sodium, 50 mg, associated with codeine, 50 mg, on the control of pain, swelling, and trismus after extraction of impacted third molars.

Materials and Methods: Fifteen healthy patients with a mean age of 22.8 years (SD, 12.62 years) received a single oral dose of either drug 1 hour before each surgical procedure (left and right teeth). At 24, 48, and 72 hours after surgery, swelling was determined by use of linear measurements on the face and trismus was determined by maximal mouth opening. Postoperative pain was self-recorded by the patients using a numerical rating scale at 24-hour intervals for a period of 72 hours. Data analysis involved descriptive statistics and Shapiro-Wilk, Wilcoxon, and paired *t* tests ($P < .05$).

Results: Dexamethasone controlled pain ($P = .016$) and edema ($P = .08$) within 48 hours better than diclofenac sodium associated with codeine. No statistically significant differences were found between drugs regarding trismus and consumption of rescue analgesics (acetaminophen).

Conclusions: The results of this study suggest that pre-emptive administration of dexamethasone, 8 mg, showed better control of pain and swelling in bilateral extractions of third impacted mandibular molars.

© 2017 American Association of Oral and Maxillofacial Surgeons

J Oral Maxillofac Surg 76:60-66, 2018

Effects of a Single-Dose of Pre-Emptive Pregabalin on Postoperative Pain and Opioid Consumption After Double-Jaw Surgery: A Randomized Controlled Trial

Ali Abiskalioglu, MD,* İlker İnce, MD,† Mehmet Aksoy, MD,‡ Ertan Yalcin, DDS, PhD,§
Elif Oral Abiskalioglu, MD,|| and Adnan Kilinc, DDS, PhD¶

Purpose: The effect of a single-dose of pre-emptive pregabalin is still unknown, although it is used as an adjuvant in controlling acute postoperative pain. The purpose of this study was to evaluate the effects of pre-emptive single-dose pregabalin on postoperative acute pain and 24-hour opioid consumption in patients who underwent double-jaw surgery.

Patients and Methods: Forty patients (18 to 45 yr old; American Society of Anesthesiologists status I to II) for whom elective double-jaw surgery was planned under general anesthesia were included in this study, which had been planned as a prospective, randomized, and double-blinded study. Patients were randomly divided into 2 groups: the pregabalin group (n = 20) was given pregabalin 150 mg orally 1 hour before general anesthesia and the placebo group (n = 20) was given an oral placebo capsule. The groups were administered the routine general anesthesia protocol. Postoperative analgesia was performed intravenously in the 2 groups twice a day with dexketoprofen trometamol 50 mg and patient-controlled analgesia with fentanyl. Postoperative analgesia was evaluated using the visual analog scale (VAS). Fentanyl consumption, additional analgesia requirement, and side-effects were recorded during the first 24 hours after surgery. Descriptive and bivariate statistics were computed, and significance was set at a *P* value less than .05.

Results: Compared with placebo, the VAS score was statistically lower in the pregabalin group during the early postoperative period (*P* < .05). The 24-hour opioid consumption was significantly higher in the placebo group compared with the pregabalin group (509.40 ± 261.56 vs 260.10 ± 246.53 μ g, respectively; *P* = .004). In addition, the analgesia requirement was statistically lower in the pregabalin group (*P* < .05). Nausea or vomiting was observed more often in the placebo group, whereas other side-effects were similar for the 2 groups.

Conclusion: A single 150-mg dose of pre-emptive pregabalin decreased postoperative opioid consumption in the first 24 hours after double-jaw surgery. Multimodal analgesia techniques that contain pre-emptive analgesia can be used successfully in preventing postoperative pain caused by orthognathic surgery.

© 2016 American Association of Oral and Maxillofacial Surgeons
J Oral Maxillofac Surg 74:53.e1-53.e7, 2016

Assessment of Combined Local Anesthesia and Ketamine for Pain, Swelling, and Trismus After Surgical Extraction of Third Molars

Tülin Satılmış, MD, Hasan Garip, DDS, PhD,†
Esra Arpacı, DDS,‡ Cem Şener, DDS, PhD,§ and
Kamil Göker, DDS, PhD,¶*

Purpose: The aim of this study was to assess the clinical efficacy of combined treatment with local anesthetic and subanesthetic ketamine for the relief or prevention of postoperative pain, swelling, and trismus after the surgical extraction of third molars.

Patients and Methods: Fifty patients undergoing the extraction of impacted mandibular third molars were included in the study. The patients were randomly divided into 2 groups: local anesthetic alone (LAA) and local anesthetic plus ketamine (LAK). The patients in the LAA group received 5 mL of a local anesthetic and saline combination comprising 2 mL of local anesthetic and 3 mL of saline. The patients in the LAK group received 5 mL of a local anesthetic, ketamine, and saline combination comprising 2 mL of local anesthetic and 0.3 mg/kg ketamine and saline.

Results: Facial swelling on postoperative days was significantly lower in the LAK group than in the LAA group ($P = .0001$). The mouth opening on the postoperative days was significantly greater in the LAK group than in the LAA group ($P = .0001$). The pain scores on the VAS at 30 minutes and 1, 4, 12, and 24 hours after surgery were significantly higher in the LAA group than in the LAK group ($P = .0001$, $P = .005$).

Conclusion: The combination of a local anesthetic and subanesthetic doses of ketamine during surgical extraction of third molars can produce good local anesthesia while affording a comfortable procedure for the surgeon and patient and providing good postoperative analgesia with less swelling and significantly less trismus.

© 2009 American Association of Oral and Maxillofacial Surgeons
J Oral Maxillofac Surg 67:1206-1210, 2009

REGIONAL ANESTHESIA AND ACUTE PAIN

SPECIAL ARTICLE

OPEN

Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Acute Pain Management From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists

Eric S. Schwenk, MD, Eugene R. Viscusi, MD,* Asokumar Buvanendran, MD,† Robert W. Hurley, MD, PhD,‡
Ajay D. Wasan, MD, MSc,§ Samer Narouze, MD, PhD,|| Anuj Bhatia, MD, MBBS,** Fred N. Davis, MD,††
William M. Hooten, MD,‡‡ and Steven P. Cohen, MD§§*

Guidelines recommend:

- Bolus doses up to 0.35 mg/kg
- Infusion dose up to 1 mg/kg per hour in settings without intensive monitoring

Liposome Bupivacaine

EXPAREL[®]
(bupivacaine liposome injectable suspension)

OPIOID FREE

- Indicated for administration into the surgical site to produce postsurgical analgesia.
- Only for local infiltration
- Do not administer is same site as local anesthetic

What would you prescribe?

**AMY P. FROM COLUMBUS
WRECKED HER CAR
TO GET MORE
PRESCRIPTION OPIOIDS.**



Thank you for your attention!



"Your insurance will cover your entire operation, but only if performed by our office receptionist."

Work Cited

- <http://www.flhealthsource.gov/FloridaTakeControl/>
- <http://www.floridahealth.gov/statistics-and-data/e-forcse/>
- http://laws.flrules.org/files/Ch_2018_013.pdf
- https://www.aaoms.org/docs/govt_affairs/advocacy_white_papers/prescription_drug_abuse_prevention.pdf
- https://www.aaoms.org/docs/govt_affairs/advocacy_white_papers/opioid_prescribing.pdf
- <https://www.cdc.gov/vitalsigns/pdf/2017-07-vitalsigns.pdf>
- CDC Risk mitigation strategies to reduce opioid overdoses - <https://stacks.cdc.gov/view/cdc/43692>
- <https://www.hhs.gov/opioids/>
- <https://opioids.thetruth.com/o/articles/amy>
- Niodita Gupta, Marko Vujicic, Andrew Blatz, Opioid prescribing practices from 2010 through 2015 among dentists in the United States: What do claims data tell us?, *The Journal of the American Dental Association*, Volume 149, Issue 4, 2018, Pages 237-245.e6, ISSN 0002-8177, <https://doi.org/10.1016/j.adaj.2018.01.005>.
- Wick EC, Grant MC, Wu CL. Postoperative Multimodal Analgesia Pain Management With Nonopioid Analgesics and TechniquesA Review. *JAMA Surg.* 2017;152(7):691–697. doi:10.1001/jamasurg.2017.0898

TABLE 6. Summary of ASRA/AAPM Recommendations for Subanesthetic Ketamine in Acute Pain

| Recommendation Category | Recommendation | Level of Evidence* |
|--------------------------------|---|--|
| Indications for use | (1) Perioperative use in surgery with moderate to severe postoperative pain (2) Perioperative use in patients with opioid tolerance (3) As analgesic adjunct in opioid-tolerant patients with sickle cell crisis (4) As analgesic adjunct in patients with OSA | (1) Grade B, moderate certainty (2) Grade B, low certainty (3) Grade C, low certainty (4) Grade C, low certainty |
| Dosing range | Bolus: up to 0.35 mg/kg Infusion: up to 1 mg/kg per hour | Grade C, moderate certainty |
| Relative contraindications | (1) Poorly controlled cardiovascular disease (2) Pregnancy, psychosis (3) Severe hepatic disease, ie, cirrhosis (avoid), moderate hepatic disease (caution) (4) Elevated intracranial pressure, elevated intraocular pressure | (1) Grade C, moderate certainty (2) Grade B, moderate (3) Grade C, low certainty (4) Grade C, low certainty |
| Personnel | Supervising clinician: a physician experienced with ketamine (anesthesiologist, critical care physician, pain physician, emergency medicine physician) who is ACLS certified and trained in administering moderate sedation Administering clinician: registered nurse or physician assistant who has completed formal training in safe administration of moderate sedation and is ACLS certified | Grade A, low certainty (see Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain from ASRA, AAPM, and ASA) ³⁵ |

*Evidence was evaluated according to the USPSTF grading of evidence, which defined levels of evidence based on magnitude and certainty of benefit.⁵

Adjunctive Therapies for Post-operative Pain

- Long acting local anesthetic – Bupivacaine vs. Liposomal bupivacaine
- Corticosteroids – Dexamethasone
- Pre-emptive analgesic
- Gabapentanoids (Gabapentin and Pregabalin)
- Tramadol
- Ketamine

Pre-Emptive Analgesia with Ketamine for Relief of Postoperative Pain After Surgical Removal of Impacted Mandibular Third Molars

Amith Hadhimane¹ · Manjunath Shankariah² · Kiran V. Neswi²

Received: 2 November 2014 / Accepted: 29 May 2015 / Published online: 5 July 2015
© The Association of Oral and Maxillofacial Surgeons of India 2015

“The sub-mucosal injection of 0.5 mg/kg ketamine administered before surgical removal of impacted mandibular third molars was found to be effective in significantly reducing post-operative pain for the first 24 h.”